Jump to content

Search results

  • hyperoxaluria. It is an LDHA-directed small interfering RNA developed by Dicerna Pharmaceuticals. The most common side effects include injection site reactions...
    9 KB (560 words) - 03:18, 15 July 2024
  • Thumbnail for Novo Nordisk
    Novo Nordisk (category Pharmaceutical companies established in 1923)
    35 billion. In November 2021, Novo announced it would acquire Dicerna Pharmaceuticals and its RNAi therapeutics, for $3.3 billion ($38.25 per share)...
    39 KB (3,672 words) - 04:25, 30 September 2024
  • Thumbnail for Small interfering RNA
    pipeline of siRNA therapies are Dicerna Pharmaceuticals, partnered Eli Lilly and Company and Arrowhead Pharmaceuticals partnered with Johnson and Johnson...
    56 KB (6,827 words) - 12:42, 7 October 2024
  • Thumbnail for RNA interference
    that are being developed by pharmaceutical companies such as Arrowhead Pharmaceuticals, Dicerna, Alnylam Pharmaceuticals, Amgen, and Sylentis. These medications...
    141 KB (15,474 words) - 08:09, 11 August 2024
  • Thumbnail for Gene therapy
    necessarily non-viral delivery problems. Alnylam, Dicerna Pharmaceuticals, and Ionis Pharmaceuticals focus on delivery of siRNA (antisense oligonucleotides)...
    176 KB (18,162 words) - 23:14, 25 September 2024
  • forward to initial public offering a number of firms, including Dicerna Pharmaceuticals and Clovis Oncology. The firm has also provided funding to support...
    9 KB (808 words) - 10:20, 19 August 2024